Cyndeo Wealth Partners LLC Boosts Holdings in Eli Lilly and Company (NYSE:LLY)

Cyndeo Wealth Partners LLC boosted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 8.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,937 shares of the company's stock after purchasing an additional 1,045 shares during the quarter. Cyndeo Wealth Partners LLC's holdings in Eli Lilly and Company were worth $10,685,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Hanson & Doremus Investment Management boosted its position in Eli Lilly and Company by 17.7% during the first quarter. Hanson & Doremus Investment Management now owns 3,840 shares of the company's stock valued at $3,171,000 after buying an additional 578 shares during the period. Stillwater Capital Advisors LLC increased its position in Eli Lilly and Company by 18.9% during the 1st quarter. Stillwater Capital Advisors LLC now owns 1,301 shares of the company's stock valued at $1,075,000 after purchasing an additional 207 shares during the period. CHB Investment Group LLC boosted its stake in shares of Eli Lilly and Company by 1.5% during the 1st quarter. CHB Investment Group LLC now owns 3,164 shares of the company's stock valued at $2,613,000 after purchasing an additional 48 shares in the last quarter. Access Financial Services Inc. purchased a new position in shares of Eli Lilly and Company during the 1st quarter worth approximately $319,000. Finally, Acropolis Investment Management LLC lifted its stake in shares of Eli Lilly and Company by 1.1% in the 1st quarter. Acropolis Investment Management LLC now owns 1,785 shares of the company's stock valued at $1,474,000 after purchasing an additional 20 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 0.9%

Eli Lilly and Company stock traded down $6.96 during mid-day trading on Thursday, reaching $784.28. 2,441,727 shares of the company were exchanged, compared to its average volume of 3,656,357. The firm has a market cap of $743.29 billion, a P/E ratio of 63.81, a PEG ratio of 1.16 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The business has a fifty day moving average of $778.55 and a 200 day moving average of $801.58.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The firm had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. During the same period in the prior year, the firm posted $2.58 earnings per share. Eli Lilly and Company's revenue for the quarter was up 45.2% compared to the same quarter last year. Research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on LLY. Guggenheim reissued a "buy" rating on shares of Eli Lilly and Company in a research report on Friday, May 23rd. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their target price for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus price target of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.